The results of second-phase clinical trial of autologous dendritic cells vaccine with immunologic adjuvant in cutaneous melanoma patients

Voprosy Onkologii

Volumn 58, Issue 2, 2012, Pages 212-221

  Baldueva, I A ^a,d   Novik, A V ^a,e   Moiseenko, V M ^b   Nehaeva, T L ^a,d   Danilova, A B ^a   Danitov, A O ^a   Protsenko, S A ^a   Petrova, T Yu ^a   Uleyskaya, G I ^c   Schekina, L A ^c   Semenova, A I ^a   Mihaylichenko, T D ^a   Teletaeva, G M ^a   Zhabina, A S ^a   Volkov, N V ^a,b   Komarov, Yu I ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b Beresin Institute of Biologic Systems   (Russian Federation)

^c Municipal Hospital No 31   (Russian Federation)

^d I I Mechnikov North West Medical University   (Russian Federation)

^e SAINT PETERSBURG STATE PEDIATRIC MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; ALKYLATING AGENT; CANCER VACCINE; IMMUNOLOGICAL ADJUVANT;

ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELLULAR IMMUNITY; CLINICAL ARTICLE; CUTANEOUS MELANOMA; DELAYED HYPERSENSITIVITY; DISEASE COURSE; DRUG EFFICACY; FATIGUE; FEVER; FLU LIKE SYNDROME; HUMAN; INFORMED CONSENT; T LYMPHOCYTE; TREATMENT RESPONSE; VACCINATION; ADULT; AGED; CANCER STAGING; CLINICAL TRIAL; DENDRITIC CELL; DRUG ADMINISTRATION; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SKIN TUMOR; TIME; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CANCER VACCINES; CYCLOPHOSPHAMIDE; DENDRITIC CELLS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864031681     PISSN: 05073758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Alfaro C., Perez-Gracia J. L., Suarez N. et al. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with CM-CSF, pegylated INF, and cyclophosphamide for metastatic cancer patients // J. Immunol. - 2011. - Vol. 187. - P. 6130-6142.
2. Castiello L., Sabatino M., Jin P. et al. Monocyte-derived DC maturation strategies and related pathways: a transcriptional view // Cancer Immunol. Immunother. - 2011. -Vol. 60. - P. 457-466.
3. Chiang C. L., Hagemann A. R., Leskowitz R. et al. Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses // PLoS One. - 2011. - Vol. 6. - e. 28732.
4. Chiang C. L.L., Maier D. A., Kandalaft L. E. et al. Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate // J. Transl. Med. - 2011. -Vol. 9. - P. 198.
5. Chong S. Z., Wong K. L., Lin G. et al. Human CD8+ T cells drive Th1 responses through the differentiation of TNF/iNOS-producing dendritic cells // Europ. J. Immunol. - 2011. - Vol. 41. - P. 1639-1651.
6. Harada Y., Yonemitsu Y. Dramatic improvement of DC-based immunotherapy against various malignancies // Front Biosci. - 2011. - Vol. 17. - P. 2233-2242.
7. Koido S., Homma S., Takahara A. et al. Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines // J. Biomed. Biotechnol. - 2011. - P. 1-13.
8. Mackiewicz J., Mackiewicz A. Design of clinical trials for therapeutic cancer vaccines development // Europ. J. Pharmacol. - 2009. - Vol. 625. - P. 84-89.
9. Mitsui J., Nishikawa H., Muraoka D. et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals // Clin. Cancer. Res. - 2010. - Vol. 16. - P. 2781-2791.
10. Palucka K., Ueno H., Zurawski G. et al. Building on dendritic cell subsets to improve cancer vaccines // Curr. Opin. Immunol. - 2010. - Vol. 22. - P. 258-263.
11. Quezada S. A., Peggs K. S., Simpson T. R. et al. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cells depletion against established melanoma // J. Exp. Med. - 2008. -Vol. 205. - P. 2125-2138.
12. Seo M. J., Kim G. R., Son Y. M. et al. Interactions of dendritic cells with cancer cells and modulation of surface molecules affect functional properties of CD8+ T cells // Mol. Immunol. - 2011. - Vol. 48. - P. 1744-1752.
13. Toh H. C., Waang W.-W., Chia W. K. et al. Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients // Clin. Cancer Res. - 2009. - Vol. 15. - P. 7726-7736.
14. Trumpfheller C., Longhi M. P., Caskey M. et al. Dendritic cell-targeted protein vaccines: a novel approach in induce T-cell immunity // J. Intern. Med. - 2012. - Vol. 271. -P. 183-192.
15. Tuyaerts S. Dendritic cell therapy for oncology roundtable conference // J. Immun. Based Therap. Vaccines. - 2011. - Vol. 9. - P. 1-6.
16. Xu Q., Liu G., Yuan X. et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens // Stem Cells. -2009. - Vol. 27. - P. 1734-1740.